Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast Cancer
This study has been completed.
Information provided by (Responsible Party):
First received: March 18, 2005
Last updated: August 29, 2013
Last verified: August 2013
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||December 2008|
|Primary Completion Date:||December 2008 (Final data collection date for primary outcome measure)|
Kaufman B, Trudeau M, Awada A, Blackwell K, Bachelot T, Salazar V, DeSilvio M, Westlund R, Zaks T, Spector N, Johnston S. Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study. Lancet Oncol. 2009 Jun;10(6):581-8. doi: 10.1016/S1470-2045(09)70087-7. Epub 2009 Apr 24.
Kaufman B, Wu Y, Amonkar M, Sherrill B, Bachelot T, Salazar V, Viens P, Johnston S. Impact of Lapatinib Monotherapy on Quality of Life and Pain Symptoms in Patients With HER2+ Relapsed or Refractory Inflammatory Breast Cancer. [Curr Med Res Opin]. 2010;26(5):1065-1073.